胸苷激酶1和Dickkopf-1对膀胱癌患者疗效及预后的判断价值  

Effect of thymidine kinase 1 combined with Dickkopf-1 in predicting the efficacy of bladder cancer treatment and prognosis

作　　者：刘健[1] 李海珠[1] 甘瑞伟 王玥莹[1] LIU Jian;LI Hai-zhu;GAN Rui-wei;WANG Yue-ying(Department of Laboratory,The First People＇s Hospital of Zhaoqing,Zhaoqing 526000,Chin)

机构地区：[1]广东省肇庆市第一人民医院检验科,肇庆526000

出　　处：《中国肿瘤临床与康复》2018年第7期797-799,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨膀胱癌患者的血清中胸苷激酶1和Dickkopf-1的水平对疗效及预后的判断价值。方法选取2013年1月至2014年12月间广东省肇庆市第一人民医院收治的75例膀胱癌患者,同时选取来院体检的75名健康体检者进行回顾性分析,膀胱癌患者中的45例浅表性膀胱癌患者纳入浅表组,30例肌层浸润性膀胱癌患者纳入肌层组。分析并比较手术前膀胱癌患者和对照组及膀胱癌患者手术前后血清中的胸苷激酶1和Dickkopf-1水平,并比较两组膀胱癌患者的3年生存率。结果手术治疗前,浅表组和肌层组膀胱癌患者的胸苷激酶1和Dickkopf-1显著高于对照组,差异均有统计学意义(均P<0.05),浅表组与肌层组的胸苷激酶1和Dickkopf-1水平比较,差异无统计学意义(P>0.05)。治疗后,浅表组和肌层组患者的胸苷激酶1和Dickkopf-1水平均低于手术前,且浅表组患者的上述两种指标均低于肌层组患者,差异均有统计学意义(均P<0.05)。浅表组患者的三年生存率为71.1%,高于肌层组患者的36.7%,差异有统计学意义(P<0.05)。结论膀胱癌患者血清中的胸苷激酶1和Dickkopf-1水平在治疗前后差异显著,可以用其水平作为预测膀胱癌转移及评判治疗效果的辅助指标。Objective To explore the role of serum thymidine kinase 1 combined with Dickkopf-1 in the prediction of treatment efficacy and prognosis for bladder cancer. Methods Seventy-five patients with bladder cancer admitted at The First People＇s Hospital of Zhaoqing from January 2013 to December2014 were selected with 45 patients with superficial bladder cancer（ superficial group） and 30 patients with myometrium infiltrating bladder cancer（ myometrium group）. Meanwhile,75 healthy individuals who had physical examination were retrospectively analyzed. The level of thymidine kinase 1 and Dickkopf-1 in the serum in bladder cancer patients was analyzed and compared between the two groups and before and after operation. Three-year survival was compared. Results Before the operation,the serum level of thymidine kinase 1 in the superficial group and the myometrial group was significantly higher than in the control group（ all P〈0. 05）. There was no significant difference in the level thymidine kinase 1 and Dickkopf-1 between superficial group and myometrium group（ P〈0. 05）. After the treatment,the serum level of thymidine kinase 1 and Dickkopf-1 was lower than before the operation with the superficial group lower than the myometrium group（ all P〈0. 05）. The three-year survival rate was 71. 1% in the superficial group,which was higher than 36. 7% of the control group（ P〈0. 05）. Conclusion The level of thymidine kinase 1 and Dickkopf-1 in the serum in bladder cancer patients is significant different before and after treatment. It can be used as an auxiliary index to predict the metastasis of cancer and evaluate the efficacy of treatment.

关 键 词：胸苷激酶1 DICKKOPF-1 膀胱肿瘤 预后 三年生存期 

分 类 号：R737.14[医药卫生—肿瘤]